



Contra Costa Health Plan
P&T Formulary Update
June 17, 2022

Changes effective: 07/15/2022

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On June 17, 2022 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
• DPP-4 inhibitors • Atypical antipsychotics • Insomnia class • Potassium replacement and removing agents	• Contraceptive foams • Gaucher Disease
Drug Monographs	
• Sucraid • Provenge	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> • Insulin Glargine • Infliximab Biosimilars • Filgrastim and Pegfilgrastim Biosimilars <u>Updates were made to the criteria for the following agents:</u> • Orilissa • CGRP Receptor Antagonists for Headache Prevention (Emgality) • Freestyle Libre Reader and Sensor • Valbenazine (Ingrezza) and Austedo (deutetrabenazine) <u>Criteria reviewed and unchanged:</u> • Sucraid • Provenge (sipuleucel-T) <u>CCHP formulary changes were made to the following drugs:</u> • Sevelamer carbonate (Renvela) • Esomeprazole (Nexium)	
Guest Speaker(s)	

None	
<u>CCHP P&T Committee approved the following modifications to the formulary (commercial and BHC members):</u>	
Medication Name & Dosage Strength	Approved Formulary Changes
Insulin Glargine	Removed from formulary, prior authorization required
Avsola; Infliximab (Janssen) Nivestym; Releuko Nyvepria; Ziextenzo	Add to online searchable formulary, prior authorization required
Emgality	Add to online searchable formulary, prior authorization required
Sevelamer carbonate(Renvela)	Change from Tier 2-ST to unrestricted Tier 1 formulary
Januvia (sitagliptin) Janumet (sitagliptin/metformin)	Remove QL:Change from T2-QL-ST requiring metformin to Tier 2-ST requiring metformin.
Alogliptin (Nesina) Alogliptin/metformin (Kazano)	Remove QL:Change from T2-QL-ST requiring metformin to Tier 2-ST requiring metformin.
Janumet (sitagliptin/metformin) Steglujan (ertugliflozin/sitagliptin) Alogliptin/pioglitazone (Oseni)	Change from unlisted/NF to Tier 2-ST (t/f metformin)
Esomeprazole (Nexium)	Add to formulary as Tier 1
Quetiapine (seroquel)	Change from Tier 2-QL to Tier 1
Quetiapine ER (Seroquel XR)	Change QL from 30/30 to 60/30
Latuda (lurasidone); Asenapine (Saphris)	Change from non-formulary to T3 PA. Add to online searchable formulary, prior authorization required
Ziprasidone (Geodon) IM	Change from T1 to T3-PA required
Clozapine (Fazaclo)	Change from T1 to T3-PA required
Zolpidem (Ambien CR)	Changed from T3-PA to T2 QL (30/30)
Potassium chloride 10mg ER	Change from unlisted to Tier 1
SPS products	Change from T1 to NF unlisted
New Product Reviews (including new indications)	
- Takhzyro (lanadelumab-flyo) - KeraStat (ketatin) topical cream - Pyrukynd (mitapivat) tablets - Releuko (filgrastim-ayow) - Carvykti (ciltacabtagene) IV - Ibsrela (tenapanor) - Rezipres (ephedrine) - Korsuva (difelikefalin) - Mayzent (Siponimod) - Rinvoq (upadacitinib) - Verkazia (cyclosporine) 0.1% - Triumeq PD (abacavir/dolutegravir) - Quviviq (daridorexant) - Vonjo (pacritinib citrate) - Akovaz (ephedrine) IV - Rilpivirine ER - Cabotegravir ER IM - Antivert (meclizine) - Soaanz (torsemide) - Nexiclon XR (clonidine) - Nuwiq (antihemophilic) - Opdualag (nivolumab) - ProvayBlue (methylene blue) - Tlando (testosterone) capsule - Vijoice (Alpelisib) - Camcevi (leuprolide) subQ	

- Camzyos (mavacamten)